Dickkopf-1 and β-catenin as Biomarkers for Early Diagnosis of Hepatocellular Carcinoma

Mohamed, Amal Ahmed; Ghanem, Hala M.; Kamal, Maha Moustafa; Ahmed, Rehab; Madkour, Naglaa Kamal; Abdou, Dina; Talima, S.; Hawash, Nehad

doi:10.2174/1573394715666191122094659

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Des-γ-carboxyprothrombin (DCP), also known as protein induced by vitamin K absence or antagonist II (PIVKAII), can appear in the serum of patients with vitamin K absence or HCC [ 4 ]. Dickkopf-1 (DKK1) is a secretory glycoprotein that inhibits Wnt signalling pathway by binding to Wnt receptor LRP5/6 [ 5 ]. Wnt signalling pathway is an important mechanism for the occurrence and development of HCC and other tumours.…”

Section: Introductionmentioning

confidence: 99%

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

et al. 2022

View full text Add to dashboard Cite

Background Hepatocellular carcinoma lacks ideal diagnostic biomarkers. There is a lack of scientific evaluation of relevant promising biomarkers as well. Therefore this study reanalyzes the related studies of 11 blood biomarkers of HCC, and compares the diagnostic value of these biomarkers for HCC systematically. Methods The relevant literatures on the diagnostic value in HCC of 11 blood indexes in recent 5 years were searched in PubMed, Embase, and Cochrane libraries. Data were extracted and analyzed. Results Finally, 83 literature studies were brought into meta-analysis. The pooled sensitivity and specificity of AFP were 0.61 and 0.87, respectively. The AUC of AFP were 0.78. The AUC and sum of sensitivity and specificity of the combination of AFP and other biomarkers were all significantly higher than that of AFP, including AFP + AFP-L3 + DCP, AFP + DCP, AFP/DCP, AFP + GPC3. Among other biomarkers, the AUC and sum of sensitivity and specificity of biomarkers including DCP, GPC3, GP73, Hsp90alpha, midkine, and OPN were significantly higher than that of AFP. In this study, GP73 had the highest sum of sensitivity and specificity (1.78) and AUC (0.95). Conclusions The pooled sensitivity and specificity of AFP were 0.61 and 0.87, respectively. The AUC of AFP were 0.78. The combination of AFP and other biomarkers improved the diagnostic efficiency. The diagnostic value of biomarkers including DCP, GPC3, GP73, Hsp90alpha, midkine, and OPN was higher than that of AFP. GP73 had the best diagnostic value for HCC with the highest sum of sensitivity and specificity (1.78) and AUC (0.95). KEY MESSAGES The pooled sensitivity and specificity of AFP were 0.61 and 0.87, respectively. The AUC of AFP were 0.78. The combination of AFP and other biomarkers improved the diagnostic efficiency of HCC. The diagnostic value of biomarkers including DCP, GPC3, GP73, Hsp90alpha, midkine, and OPN was higher than that of AFP. GP73 had the best diagnostic value for HCC.

show abstract

Section: Introductionmentioning

confidence: 99%

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

et al. 2022

View full text Add to dashboard Cite

show abstract

“…These results are in accordance with Ren et al 27 who find a significant difference between HCC and cirrhotic patients in albumin, INR, and AFP. Paranaguá et al and Mohamed et al also find a significant difference between HCC and cirrhotic HCV patients in AST, ALT, and AFP 33,34 . Mohamed et al 35 had similar results, they found a significant difference in HCC patients in AST, ALT, and T bilirubin, INR, serum AFP, serum creatinine and platelet.…”

Section: Discussionmentioning

confidence: 77%

The role of PRDM1 gene polymorphism in the progression of hepatocellular carcinoma in Egyptian patients

Mohamed

Esmail

Ibrahim

et al. 2022

Journal of Medical Virology

View full text Add to dashboard Cite

In Egypt, hepatocellular carcinoma (HCC) ranks as the second largest cause of cancer mortality. PRDM1 is a tumor suppressor gene essential for the differentiation and regulation activity of plasma cells and T cells. It plays a vital role in T cell exhaustion of chronic viral infection and HCC. We aimed to study the role of PRDM1 gene polymorphism in HCV and HCC‐related to hepatitis C virus (HCV) progress in Egyptians. The case‐control study included 300 Egyptian patients divided into 100 HCC,100 cirrhosis, and 100 control. Laboratory investigations were done for some clinicopathological biomarkers, including liver function tests, complete blood picture, serum alpha‐fetoprotein, and hepatitis markers (HBsAg, anti‐HCV‐Ab). TaqMan allelic discrimination assay technique was used to genotype PRDM1 gene polymorphism. Multivariant analysis (logistic regression) assessed the association between the polymorphisms with HCC progression and designed the suggested model for HCC prediction. The frequencies of the G allele and GG phenotype in the control group were significantly more than that of the HCC and cirrhosis group. However, GA genotypes and A allele frequencies significantly increased in the HCC patients than in cirrhosis and controls. In addition, by comparing the HCC group and the non‐HCC group (controls and cirrhotic patients), the subjects carrying AA or GA have 2 times more risk to develop HCC than those carrying GG genotypes (odd ratio = 2.045% and 95% confidence interval are (1.123−3.722) p = 0.019). Multivariate analysis results suggested a model of Aspartate transaminase (AST), Albumin, and PRDM1 polymorphism to predict the risk of HCC in Egyptians. In addition, PRDM1 polymorphism has an association with HCC prognosis (tumor size). For PRDM1 polymorphism, the A allele and AA might be considered as HCC‐related to the HCV risk factor. In addition, AST, Albumin, and PRDM1 polymorphism predict the risk of HCC in Egyptians Therefore, the polymorphism might help in identifying the susceptible Egyptians to HCC. In addition, polymorphism might have a role in HCC prognosis.

show abstract

Liver Cancer: New Insights into Surgical and Nonsurgical Treatments

Sharifian

Baharvand

Moayyedkazemi

2021

CCTR

View full text Add to dashboard Cite

Introduction: Hepatocellular carcinoma (HCC) is the most common that has increased in the recent years around the world. Primary liver cancer or HCC is considered as the 5th and 7th most frequent cancer in males and females, respectively; whereas it is the second leading cause of cancer-related death around the world. Unfortunately, HCC is frequently diagnosed at an advanced phase; while the majority of patients are not having qualification for the remedial therapies in this stage. Furthermore, current systemic chemotherapy demonstrates low efficiency and minimum survival profits. At present, liver cancer therapy is multidisciplinary, and multiple choice treatment are considered mostly on an individualized basis based on the complex interaction of tumor stage and the degree of liver disease, and the patient’s general condition health. Methods: Here we reviewed the new insight into nonsurgical and surgical treatment of liver cancer in five English databases, including Scopus, PubMed, Web of Science, EMBASE, and Google Scholar up to December 2019. Results: The results demonstrated in addition to current therapies such as chemotherapy and surgical resection, new approaches including immunotherapy (with human monoclonal antibodies), virus therapy (with oncolytic viruses such as herpes simplex virus, adenovirus, parvovirus, poxvirus, paramyxovirus, reovirus), gene therapy by novel experimental techniques such as gene directed enzyme/prodrug therapy (P53 gene, microRNA and small-interfering RNA), new ablation therapies radiofrequency ablation, highintensity focused ultrasound, helium cryoablation therapy), as well as adjuvant therapy which widely used method after HCC surgical resection is adjuvant therapy. In recent years, biomaterials approach such ass nanoparticles, liposomes, microspheres, and nanofibers nanoparticles are also considered as the reliable and novel patents to treat and study of liver cancers. Conclusion: Multidisciplinary, and multiple choice treatment and therapy suggestions are available for this liver cancer, whereas there are differences in the management recommendations for liver cancers across specialties and geographic regions. Current findings showed that treatment strategies have combined with the advance of new treatment modalities. Moreover, the use of new approaches with higher efficacy such as combination therapy, the use of biomaterials, ablation therapy, etc are can be considered as the preferred treatments for patients.

show abstract

Dickkopf-1 and β-catenin as Biomarkers for Early Diagnosis of Hepatocellular Carcinoma

Cited by 3 publications

References 0 publications

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

A meta-analysis and of clinical values of 11 blood biomarkers, such as AFP, DCP, and GP73 for diagnosis of hepatocellular carcinoma

The role of PRDM1 gene polymorphism in the progression of hepatocellular carcinoma in Egyptian patients

Liver Cancer: New Insights into Surgical and Nonsurgical Treatments

Contact Info

Product

Resources

About